CLNN Stock Forecast 2025-2026
Distance to CLNN Price Targets
CLNN Price Momentum
10 Quality Stocks Worth Considering Now
Researching Clene (CLNN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CLNN and similar high-potential opportunities.
Latest CLNN Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, CLNN has a bullish consensus with a median price target of $30.50 (ranging from $20.00 to $84.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $3.00, the median forecast implies a 916.7% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Bruce Jackson at Benchmark, projecting a 2,700.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLNN Analyst Ratings
CLNN Price Target Range
Latest CLNN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLNN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $23.00 |
| Apr 8, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $31.00 |
| Mar 25, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $31.00 |
| Mar 24, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $31.00 |
| Mar 24, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $23.00 |
| Mar 12, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $31.00 |
| Mar 12, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $23.00 |
| Feb 25, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $31.00 |
| Feb 25, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $23.00 |
| Feb 6, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $23.00 |
| Dec 19, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $23.00 |
| Dec 10, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $23.00 |
| Nov 22, 2024 | Benchmark | Bruce Jackson | Buy | Maintains | $84.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $31.00 |
| Nov 14, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $83.00 |
| Nov 13, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $23.00 |
| Oct 24, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $23.00 |
| Oct 24, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $31.00 |
| Oct 4, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $86.00 |
| Oct 2, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $23.00 |
Clene Inc. (CLNN) Competitors
The following stocks are similar to Clene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Clene Inc. (CLNN) Financial Data
Clene Inc. has a market capitalization of $25.89M with a P/E ratio of -0.5x. The company generates $342,000 in trailing twelve-month revenue with a 79.5% profit margin.
Revenue growth is -46.5% quarter-over-quarter, while maintaining an operating margin of -9,511.0% and return on equity of -1,738.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Clene Inc. (CLNN) Business Model
About Clene Inc.
Develops nanotechnology-based therapies for neurodegenerative diseases.
Clene Inc. generates revenue by advancing its innovative therapies through clinical trials and research initiatives, targeting unmet medical needs in neurodegenerative diseases. The company focuses on treatments for conditions such as multiple sclerosis, ALS, and Parkinson's disease, leveraging its proprietary nanotechnology to enhance neuronal health.
Founded on principles of clean-surfaced nanocrystals, Clene Inc. aims to revolutionize neurotherapeutics and improve treatment options in the biotechnology and healthcare sectors. The company is based in the United States and is dedicated to pushing the boundaries of scientific innovation.
Company Information
Sector
Consumer Defensive
Industry
Packaged Foods
Employees
75
CEO
Mr. Robert Etherington MBA
Country
United States
IPO Year
2020
Website
clene.comClene Inc. (CLNN) Latest News & Analysis
Clene Inc. (Nasdaq: CLNN) will present at the Emerging Growth Conference, focusing on therapies for neurodegenerative diseases like ALS and MS.
Clene Inc.'s presentation at the Emerging Growth Conference highlights its focus on neurodegenerative diseases, potentially attracting investor interest and impacting stock performance.
Clene Inc. (Nasdaq: CLNN) will present at the Jones Healthcare and Technology Innovation Conference and hold 1x1 investor meetings, focusing on neurodegenerative disease treatments.
Clene Inc.'s presentation at a major conference signals potential advancements in neurodegenerative treatments, which could attract investor interest and impact stock performance.
Clene Inc. (Nasdaq: CLNN) reported its full year 2024 financial results, focusing on its clinical programs for treating ALS and MS, as part of its strategy in neurodegenerative disease therapies.
Clene Inc.'s financial results and updates on clinical programs for ALS and MS could impact investor confidence, signaling potential growth or risks in the biopharmaceutical sector.
Clene Inc. (CLNN) reported a quarterly loss of $1.67 per share, exceeding the Zacks Consensus Estimate of a $1.21 loss, and worsening from a loss of $1.20 per share year-over-year.
Clene Inc.'s larger-than-expected quarterly loss signals worsening financial performance, potentially impacting investor confidence and stock valuation negatively.
The HEALEY ALS Platform Trial's new cross-regimen analysis indicates a significant survival advantage, which may impact investor interest in related biotechnology firms.
The significant survival advantage reported in the HEALEY ALS trial may boost investor confidence in biotech stocks involved in ALS treatments, potentially leading to increased funding and stock prices.
Clene Inc. (Nasdaq: CLNN) will participate in the 37th Annual Roth Conference and host 1x1 investor meetings, focusing on treatments for ALS and MS.
Clene Inc.'s participation in a major conference highlights its commitment to advancing treatments for neurodegenerative diseases, potentially attracting investor interest and boosting stock performance.
Frequently Asked Questions About CLNN Stock
What is Clene Inc.'s (CLNN) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Clene Inc. (CLNN) has a median price target of $30.50. The highest price target is $84.00 and the lowest is $20.00.
Is CLNN stock a good investment in 2025?
According to current analyst ratings, CLNN has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CLNN stock?
Wall Street analysts predict CLNN stock could reach $30.50 in the next 12 months. This represents a 916.7% increase from the current price of $3.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Clene Inc.'s business model?
Clene Inc. generates revenue by advancing its innovative therapies through clinical trials and research initiatives, targeting unmet medical needs in neurodegenerative diseases. The company focuses on treatments for conditions such as multiple sclerosis, ALS, and Parkinson's disease, leveraging its proprietary nanotechnology to enhance neuronal health.
What is the highest forecasted price for CLNN Clene Inc.?
The highest price target for CLNN is $84.00 from Bruce Jackson at Benchmark, which represents a 2,700.0% increase from the current price of $3.00.
What is the lowest forecasted price for CLNN Clene Inc.?
The lowest price target for CLNN is $20.00 from at , which represents a 566.7% increase from the current price of $3.00.
What is the overall CLNN consensus from analysts for Clene Inc.?
The overall analyst consensus for CLNN is bullish. Out of 9 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.50.
How accurate are CLNN stock price projections?
Stock price projections, including those for Clene Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.